VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 10, 2012) - Pyng Medical Corp. (the "Company") (TSX VENTURE:PYT) announced today that the FAST1® has been chosen by the Spanish Army through Pyng's exclusive dealer in Spain, International Emergency Services (IES), as the standard of care for their army combat medics to carry in their medical bags. Currently used by most NATO forces including the United States, United Kingdom, Australia, Germany and Norway, the Spanish Army is the latest force to select the FAST1 Intraosseous Infusion System for their vascular access needs.
Responsible for land-based military operations, the Spanish Army (Ejército de Tierra - "Ground Army") is the terrestrial army of the Spanish Armed Forces. After much consideration and research, the Spanish Army decided that the sternal route for intraosseous infusion was the best way to administer emergency fluids and medications in battlefield situations.
"In the past, the Spanish Army has used the EZ-IO® and BIG® (Bone Injection Gun) systems for their intraosseous needs. However, they found that soldiers would have injuries to their extremities, exactly where these devices require deployment. They realized that the sternum was a better access point as it is one of the most protected parts on a soldier's body," commented Jesus Orbe, Director of Sales and Marketing at IES Spain.
"The FAST1 really is a product like no other on the market. Its design and ease of use takes the guesswork out of the intraosseous infusion process. From the target patch to the automated depth control, the medic just has to find the sternal notch and deploy the device. It is easy to learn and deploy, even in low light conditions," added Mr. Orbe. "These benefits in particular are the very reasons why the FAST1 is the device of choice for the Spanish Army's intraosseous needs."
The first order of FAST1 for the Spanish Army will be used for a contingent of soldiers that are being deployed to Lebanon in the coming weeks. "We are honored to offer a product such as the FAST1 with its high degree of success, ease-of-use and dependability," noted Mr. Orbe.
About International Emergency Services
International Emergency Services is a Spanish distributor of emergency medical supplies. For more information, please visit their website at www.ies-spain.com.
About Pyng Medical Corp.
Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Pyng's expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide.
Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.
Neither the TSX Venture Exchange nor its Regulatory Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.